LRMR
Larimar·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LRMR
Larimar Therapeutics, Inc.
A clinical-stage biotechnology company that developing treatments for complex rare diseases
Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania 19004
--
Larimar Therapeutics, Inc., was incorporated under the laws of the State of Delaware on November 22, 2005. The Company is a clinical-stage biotechnology company focused on developing treatments for patients with complex rare diseases using the Company's novel Cell-Penetrating Peptide (" CPP ") technology platform.
Company Financials
EPS
LRMR has released its 2025 Q3 earnings. EPS was reported at -0.61, versus the expected -0.42, missing expectations. The chart below visualizes how LRMR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
